Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.
According to Jiangsu Hengrui Medicine Co., Ltd.'s latest financial reports the company's current earnings (TTM) are $644.73 M. The earnings displayed on this page is the company's Pretax Income.
Year | Income Before Tax | Net Income |
---|---|---|
2023 | $644.73 M | $594.35 M |
2022 | $548.22 M | $539.64 M |
2021 | $616.99 M | $625.82 M |
2020 | $952.56 M | $874.22 M |
2019 | $836.56 M | $736.03 M |
2018 | $621.52 M | $561.64 M |
2017 | $519.31 M | $444.36 M |
2016 | $416.25 M | $357.65 M |
2015 | $353.92 M | $299.99 M |
2014 | $248.61 M | $209.37 M |
2013 | $204.25 M | $171.04 M |
2012 | $186.01 M | $148.83 M |
2011 | $147.13 M | $121.1 M |
2010 | $118.83 M | $100.04 M |
2009 | $107.85 M | $91.97 M |
2008 | $64.93 M | $58.43 M |
2007 | $70.65 M | $57.04 M |
2006 | $39.96 M | $28.55 M |
2005 | $30.49 M | $22.41 M |
2004 | $23.85 M | $16.94 M |
2003 | $20.82 M | $13.06 M |
2002 | $15.27 M | $10.91 M |
2001 | $13.49 M | $11.21 M |
2000 | $11.31 M | $9.02 M |
1999 | $8.66 M | $7.09 M |
1998 | $7.2 M | $5.97 M |
1997 | $6.15 M | $5.67 M |